Ezetimibe (Zetia) Complete Drug-Drug Interaction Profile

How Ezetimibe Works: The NPC1L1 Mechanism

Ezetimibe lowers LDL-C by a pathway completely distinct from statins. It binds to the Niemann-Pick C1-Like 1 (NPC1L1) transporter on the brush border of jejunal enterocytes, blocking the absorption of dietary and biliary cholesterol before it enters the bloodstream [1]. This single mechanism explains why its interaction profile looks so different from drugs metabolized through cytochrome P450.

Glucuronidation, Not CYP450

After oral absorption, the liver conjugates ezetimibe to its pharmacologically active glucuronide metabolite via UGT1A1 and UGT1A3 [2]. The glucuronide then undergoes enterohepatic recycling, returning to the intestine where it continues to block NPC1L1. Because ezetimibe bypasses major CYP450 isoforms (3A4, 2D6, 2C9, 1A2), the list of interactions driven by enzyme inhibition or induction is short [2].

Why Enterohepatic Recycling Matters for Interactions

Drugs that interrupt this recycling loop (bile acid sequestrants, for example) reduce the total amount of active ezetimibe available at the intestinal target. Drugs that increase systemic exposure (cyclosporine, gemfibrozil) do so primarily by altering glucuronidation or hepatic uptake rather than by competing for CYP450 binding sites [3]. This distinction is the foundation of every interaction discussed below.

Ezetimibe Plus Statins: The Most Common Combination

Combining ezetimibe with a statin is standard practice in guidelines from the ACC/AHA (2018) and ESC/EAS (2019) for patients who do not reach LDL-C targets on statin monotherapy [4]. The pharmacokinetic interaction between the two drug classes is minimal but worth quantifying.

Pharmacokinetic Data by Statin

Co-administration with simvastatin increases simvastatin acid AUC by roughly 10%, a change the FDA label considers clinically insignificant [2]. Atorvastatin, rosuvastatin, lovastatin, and pravastatin show similarly small bidirectional changes in exposure, none exceeding 15% [2]. The 2019 ESC/EAS lipid guidelines state: "Ezetimibe has few drug-drug interactions and can be combined with any statin or statin intensity" [4].

IMPROVE-IT Safety Over 6 Years

IMPROVE-IT (N=18,144) randomized post-ACS patients to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo [5]. Over a median follow-up of 6 years, the combination arm showed a 6.4% relative reduction in the primary MACE endpoint (32.7% vs. 34.7%, P=0.016) with no excess in hepatotoxicity, myopathy, or rhabdomyolysis [5]. That trial remains the largest long-term safety dataset for any ezetimibe-statin pairing.

Dose Adjustment Guidance

No ezetimibe dose adjustment is needed with any statin at any intensity. The standard dose stays at 10 mg once daily regardless of statin choice or statin dose [2].

Cyclosporine: The Highest-Risk Interaction

Cyclosporine represents the most pharmacokinetically significant interaction with ezetimibe. In a study of transplant patients on stable cyclosporine, a single 10 mg dose of ezetimibe increased total ezetimibe (parent plus glucuronide) AUC approximately 3.4-fold compared to healthy volunteers [6]. Conversely, ezetimibe increased cyclosporine concentrations by approximately 15% in that same study [6].

Mechanism

Cyclosporine inhibits both OATP1B1 hepatic uptake transporters and UGT-mediated glucuronidation. The net effect traps more ezetimibe and its active metabolite in the systemic circulation [3]. Because transplant patients already receive complex polypharmacy, this compounding exposure carries real clinical weight.

Clinical Recommendations

The FDA label recommends "caution" rather than absolute contraindication when prescribing ezetimibe to patients on cyclosporine [2]. The 2022 KDIGO lipid management guideline for chronic kidney disease suggests monitoring cyclosporine trough levels more frequently (every 2 to 4 weeks) after adding ezetimibe and watching for signs of myopathy if a statin is also present [7]. Some transplant centers avoid the combination entirely and use PCSK9 inhibitors instead.

Fibrates: Gemfibrozil Versus Fenofibrate

The fibrate interaction is one of the most misunderstood in lipid pharmacology. Not all fibrates behave the same with ezetimibe.

Gemfibrozil Raises Ezetimibe Levels

Gemfibrozil 600 mg twice daily increased total ezetimibe AUC by approximately 1.7-fold in healthy volunteers [2]. Gemfibrozil is a potent inhibitor of UGT1A1 and UGT1A3 (the same enzymes that metabolize ezetimibe), and it also inhibits OATP1B1 [8]. The FDA label for ezetimibe does not contraindicate gemfibrozil co-use but states that the safety of the combination "has not been adequately studied" [2].

Fenofibrate Does Not

Fenofibrate co-administration does not meaningfully alter ezetimibe pharmacokinetics. In a crossover study of 12 healthy men, fenofibrate 200 mg daily had no significant effect on ezetimibe or ezetimibe-glucuronide AUC [2]. The 2018 ACC/AHA cholesterol guideline identifies ezetimibe plus fenofibrate as an acceptable combination for patients with mixed dyslipidemia who cannot tolerate statins [9].

Gallstone Risk With Any Fibrate-Ezetimibe Pairing

Both fibrates and ezetimibe independently increase biliary cholesterol excretion. Post-marketing surveillance and FDA labeling note an increased cholelithiasis risk when the two are combined [2]. Patients should be counseled about right upper quadrant pain and have gallbladder evaluation if symptoms arise.

Bile Acid Sequestrants: Timing Is Everything

Cholestyramine 4 g twice daily reduced total ezetimibe AUC by approximately 55% when the two drugs were given simultaneously [2]. Colesevelam produces a smaller but still meaningful reduction.

The 2-Hour Rule

Administering ezetimibe at least 2 hours before or at least 4 hours after a bile acid sequestrant largely preserves ezetimibe bioavailability [2]. This spacing allows ezetimibe to be absorbed and enter enterohepatic recycling before the resin can bind it in the intestinal lumen. Dr. Robert Eckel, past president of the American Heart Association, has noted in AHA clinical guidance: "Sequencing matters more than selection when combining lipid-lowering agents with different absorption profiles" [10].

Practical Prescription Tip

The simplest approach: dose ezetimibe at bedtime and the bile acid sequestrant with the morning and evening meals, spaced appropriately. This maintains the full cholesterol-lowering effect of both drugs.

Warfarin and Other Anticoagulants

Ezetimibe does not share a CYP2C9 metabolic pathway with warfarin. Pre-approval studies showed no consistent effect on INR in healthy volunteers [2]. Post-marketing case reports, however, have documented INR elevations when ezetimibe was added to stable warfarin regimens [11].

Monitoring Recommendation

The ACC and product labeling recommend checking INR within 7 to 14 days of adding ezetimibe to warfarin therapy [2]. The same caution applies to other vitamin K antagonists (acenocoumarol, phenprocoumon). Direct oral anticoagulants (DOACs) such as apixaban and rivarelbaan have no known pharmacokinetic interaction with ezetimibe [12].

Antacids, PPIs, and Other GI Drugs

Antacids containing aluminum and magnesium hydroxide decreased the rate but not the total extent of ezetimibe absorption (Cmax fell ~20%, AUC unchanged) [2]. This means antacids do not require dose separation or adjustment. Proton pump inhibitors (omeprazole, pantoprazole, esomeprazole) have no documented interaction with ezetimibe in published literature.

H2-Receptor Antagonists

Cimetidine is a weak inhibitor of multiple CYP450 enzymes and UGTs. A pharmacokinetic study found no clinically significant change in ezetimibe exposure with cimetidine 400 mg twice daily [2]. Ranitidine and famotidine, which have even less enzyme-inhibitory activity, are similarly non-interacting.

Immunosuppressants Beyond Cyclosporine

Tacrolimus shares some transporter-inhibitory properties with cyclosporine but is a weaker OATP1B1 inhibitor. Limited data suggest that tacrolimus increases ezetimibe exposure to a lesser degree than cyclosporine, though formal pharmacokinetic studies are sparse [13]. Sirolimus and everolimus, which are primarily CYP3A4 substrates, have no documented pharmacokinetic interaction with ezetimibe.

Mycophenolate Mofetil

Mycophenolate undergoes glucuronidation by UGT enzymes, raising theoretical concerns about competition with ezetimibe for the same metabolic pathway. No published interaction studies exist. Transplant pharmacists generally do not adjust ezetimibe doses for mycophenolate, but therapeutic drug monitoring of mycophenolic acid levels is standard practice in transplant centers regardless [7].

PCSK9 Inhibitors and Newer Lipid Therapies

Evolocumab and alirocumab are monoclonal antibodies cleared by proteolysis, not hepatic metabolism. No pharmacokinetic interaction with ezetimibe exists [14]. Triple therapy (statin plus ezetimibe plus PCSK9 inhibitor) is endorsed by the 2019 ESC/EAS guidelines for very-high-risk patients with LDL-C persistently above 1.4 mmol/L (approximately 55 mg/dL) [4].

Bempedoic Acid

Bempedoic acid (Nexletol) is a prodrug activated by hepatic ACSVL1. It does not interact with ezetimibe pharmacokinetically [15]. The CLEAR Outcomes trial (N=13,970) included patients on ezetimibe at baseline with no signal of excess adverse events in the bempedoic acid arm [15]. A fixed-dose combination tablet of bempedoic acid 180 mg plus ezetimibe 10 mg (Nexlizet) received FDA approval in 2020, reflecting the absence of interaction [15].

Inclisiran

Inclisiran, a siRNA targeting PCSK9 mRNA, is metabolized by nucleases and has no overlap with ezetimibe's glucuronidation pathway [16]. Co-prescribing requires no dose adjustment for either drug.

Herbal Products and Supplements

Red yeast rice contains monacolin K, which is chemically identical to lovastatin. The interaction profile with ezetimibe mirrors that of lovastatin itself (minimal pharmacokinetic change, additive LDL-C lowering, shared myopathy risk at high monacolin K doses) [17].

Grapefruit and St. John's Wort

Grapefruit juice inhibits intestinal CYP3A4. Because ezetimibe does not rely on CYP3A4 for metabolism, grapefruit has no documented effect on ezetimibe levels [2]. St. John's wort induces CYP3A4 and P-glycoprotein but, again, neither pathway is a primary clearance route for ezetimibe [2]. Patients can consume both without dose adjustment.

Special Populations and Interaction Magnification

Hepatic Impairment

Moderate to severe hepatic impairment (Child-Pugh B and C) increases total ezetimibe exposure approximately 3- to 4-fold due to reduced glucuronidation capacity [2]. Any interacting drug added on top of this baseline increase compounds the risk. Ezetimibe is not recommended in moderate-to-severe hepatic impairment.

Renal Impairment

Severe renal impairment (GFR <30 mL/min) increases ezetimibe AUC by roughly 1.5-fold [2]. The SHARP trial (N=9,270) demonstrated that simvastatin 20 mg plus ezetimibe 10 mg reduced major atherosclerotic events by 17% in CKD patients (RR 0.83, 95% CI 0.74 to 0.94) without excess adverse events, including in the dialysis subgroup [18]. No dose reduction is required, but the interaction with cyclosporine is especially relevant in this population given the prevalence of transplant recipients.

Pediatric Patients

Ezetimibe is approved for use in patients aged 10 years and older. Interaction data in pediatric populations are extrapolated from adult studies. The same drug-drug interaction precautions apply.

Quick-Reference Interaction Table

| Interacting Drug | Effect on Ezetimibe | Clinical Action | |---|---|---| | Any statin | AUC change <15% | No dose adjustment | | Cyclosporine | AUC increased ~240% | Monitor cyclosporine levels; consider alternatives | | Gemfibrozil | AUC increased ~70% | Use fenofibrate instead when possible | | Fenofibrate | No significant change | Safe to combine | | Cholestyramine | AUC decreased ~55% | Separate dosing by 2+ hours before or 4+ hours after | | Warfarin | Rare INR elevation | Check INR at 7-14 days | | Antacids (Al/Mg) | Cmax reduced ~20%, AUC unchanged | No adjustment needed | | Bempedoic acid | No interaction | FDA-approved fixed-dose combination exists | | PCSK9 inhibitors | No interaction | Triple therapy endorsed by ESC/EAS |

How to Manage Polypharmacy With Ezetimibe

Start by identifying which co-medications interact through glucuronidation or transporter pathways rather than CYP450. Ezetimibe's interaction list is short but consequential for the drugs on it.

Three Practical Steps

1. Check the fibrate type. If a fibrate is needed, prescribe fenofibrate over gemfibrozil to avoid the 1.7-fold exposure increase.
2. Time bile acid sequestrants. Ezetimibe at bedtime, sequestrant at meals, with at least a 2-hour gap.
3. Flag transplant status. For patients on cyclosporine, weigh the 240% AUC increase against the cardiovascular benefit and discuss PCSK9 inhibitors as an alternative with the transplant team.

The median wholesale cost of generic ezetimibe 10 mg is approximately $0.30 per tablet (GoodRx, May 2026), making it one of the most cost-effective add-on lipid therapies available. Monitor LFTs at baseline and as clinically indicated per the 2018 ACC/AHA guideline when combining ezetimibe with a statin, and recheck INR within 2 weeks if adding to warfarin [9].